Key result
The EV71 vaccine's real-world effectiveness on the onset of hand, foot, and mouth disease in children aged ≤5 years was discussed, though no quantitative results were reported in the abstract.
Why the study?
There is limited analysis of the EV71 vaccine's real-world effect based on surveillance data, and the protection of the EV71 vaccine remains controversial.
Real-world EV71 vaccine effectiveness data remain insufficient; leaves open questions for quantitative pediatric studies.
DEAR EDITOR—We read an intriguing paper discussing the clinical and epidemiological characteristics of Hand, foot, and mouth disease (HFMD) in J Infect.1 EV71 and coxsackievirus 16 (CV16) are the primary causes of HFMD.2,3 Since December 2015, four inactivated HFMD vaccines have been launched in China. There is limited analysis of the EV71 vaccine's real-world effect based on surveillance data. Moreover, the protection of the EV71 vaccine remains controversial.4-6
No takes yet. Share an insight, caveat, or question.
Fan et al. (2024) conducted a letter in Hand, foot, and mouth disease (HFMD). EV71 vaccine was evaluated on Onset of hand, foot, and mouth disease. The EV71 vaccine's real-world effectiveness on the onset of hand, foot, and mouth disease in children aged ≤5 years was discussed, though no quantitative results were reported in the abstract.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: